Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Sigma-1 receptor agonistketamine, phencyclidine, methoxetamine +3 moreketamine, phencyclidine, methoxetamine, 2-fluorodeschloroketamine, 3-MeO-PCP, dextromethorphan show less
Deschloroketamine
DCK (deschloroketamine) is a synthetic dissociative of the arylcyclohexylamine class. It is structurally the simplest structural analog of ketamine, more potent by weight and substantially longer lasting.[1] It blocks glutamate signaling in the brain, disconnecting normal sensory processing and producing the characteristic dissociative state.[2][3]
DCK (deschloroketamine) is a synthetic dissociative of the arylcyclohexylamine class. It is the simplest structural analog of ketamine, distinguished by higher weight-potency and a substantially longer duration of action.[1] DCK is an NMDA receptor antagonist, producing its effects by blocking glutamate-gated ion channels in a use-dependent manner.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Sigma-1 receptor agonistketamine, phencyclidine, methoxetamine +3 moreketamine, phencyclidine, methoxetamine, 2-fluorodeschloroketamine, 3-MeO-PCP, dextromethorphan show less
DCK was first synthesized in the 1960s during the same arylcyclohexylamine research program that produced Ketamine and phencyclidine, proposed as an immunomodulatory agent but never developed for medicine.[1] It resurfaced on research chemical markets around 2015, sometimes sold as "ketamine" to uninformed buyers.[4] Today it remains unscheduled in most jurisdictions, circulating through online research chemical vendors.
Subjective effects include dissociative anaesthesia, perceptual distortion, bodily detachment, cognitive disconnection, euphoria, and ego dissolution at higher doses. The experience is warmer and more immersive than ketamine — unfolding gradually and sustaining intensity over hours, lending itself to contemplative introspection when the setting is calm. Disorientation, prolonged confusion, and impaired motor coordination are characteristic unwanted effects.
DCK produces meaningful dependence — animal studies show it is both rewarding and reinforcing, mirroring ketamine's profile.[5] The longer duration means more cumulative exposure per session, potentially amplifying psychological strain and organ-level risks over time. No human study has been published — the evidence base rests on animal data, lab studies, forensic cases, and user reports.
History[edit]
Discovery
Deschloroketamine (DCK) was first synthesized in the 1960s during the systematic arylcyclohexylamine research program that produced ketamine and phencyclidine.[1] It was proposed as a candidate immunomodulatory and anti-infective agent. It never advanced into clinical development, and the original paper describing it has not been located in the published literature.citation needed
Emergence as a research chemical
DCK reappeared on online research chemical platforms around 2015 and triggered its first formal early warning notification in the United Kingdom that year.[4] In some markets it was sold as "ketamine," misleading buyers.[4] The first published analytical characterisation from seized material appeared in 2016.[6]
Modern research
Research milestones include enantiomer synthesis in 2018,[1] metabolite identification in 2020,[4] the first post-mortem forensic case in 2021,[7] and the first self-administration study in mice in 2022.[8][5] No clinical trials have been registered as of April 2026.
The name "deschloroketamine" is a systematic descriptor: des- (removal of) + chloro (the chlorine atom) + ketamine — literally, ketamine with its chlorine stripped away. The abbreviation DCK is standard in both research chemical communities and the analytical literature, reflecting the compound's niche circulation among informed users rather than broad recreational markets.
Chemistry[edit]
Structural class
DCK belongs to the arylcyclohexylamine family — the same chemical class as ketamine, phencyclidine, and methoxetamine. It is the structurally simplest ketamine structural analog, retaining the core molecular scaffold but lacking the chlorine atom that defines ketamine. Its molecular formula is C₁₃H₁₇NO (molecular weight 203.28 g/mol).
Pharmacology[edit]
Mechanism of action
DCK blocks glutamate signaling in the brain. It enters glutamate receptor channels after they open and stops ion flow — a pattern that requires the receptor to be active first.[2][3] This is the same mechanism as ketamine and phencyclidine,[9] and the designation rests on structural analogy with ketamine confirmed in animal studies.[8]
Behavioural pharmacology
In animal studies, DCK is both rewarding and reinforcing — mice will seek it out and self-administer it.[5] It also raises dopamine levels, the chemical signal underlying the brain's reward response.[5] This places it in the same dependence category as ketamine.[8]
Pharmacokinetics
No human pharmacokinetic data exist. In rats, DCK and its primary breakdown product reach higher concentrations in the brain than in the blood, confirming efficient brain penetration.[4] Hepatic breakdown appears slower than ketamine's, consistent with DCK's longer duration of action.[10]
Neuroscience[edit]
Where it acts
No neuroimaging or electrophysiology data exist for DCK specifically. Based on ketamine's well-studied neuroscience, blocking glutamate receptors in the brain's sensory relay — the thalamus — prevents signals from reaching the cortex normally. At lower doses this produces altered perception and bodily detachment; at higher doses, near-complete dissociative anaesthesia.
Why it matters
DCK also raises dopamine levels in cell culture.[5] Dopamine is the brain's primary reward signal, which explains both the euphoric quality users report and the reinforcing properties seen in animal models. Whether DCK's longer duration of glutamate blockade produces distinct effects on brain plasticity compared to ketamine remains unknown.
Whether DCK triggers rapid synaptogenesis through the same pathway implicated in ketamine's antidepressant effects — and whether its longer receptor engagement amplifies that process — is unknown. No data exist on whether chronic DCK use produces the white matter changes or bladder innervation damage seen with chronic ketamine. Without imaging studies, the relationship between administered dose and actual receptor engagement in the human brain remains entirely unknown.
Subjective Effects[edit]
DCK's defining quality is its gradual, sustained character. Where most dissociatives deliver intensity in a steep arc, DCK unfolds slowly and holds — producing a spacious, immersive state that users describe as warm rather than clinical. Set and setting exert strong influence on whether this quality feels contemplative or disorienting.
Within the dissociative class, DCK sits between ketamine's brief, steep dissociation and the longer, sometimes manic quality associated with methoxetamine.[11] The experience is warmer and more inward-facing than ketamine, without the forceful character sometimes attributed to methoxetamine.
Proposed as a candidate immunomodulatory agent during 1960s arylcyclohexylamine research, DCK never entered clinical development.[1] It re-emerged on research chemical markets around 2015 and received its first analytical characterisation from seized material in 2016.[4] It remains unscheduled in most jurisdictions and circulates primarily through online research chemical vendors.
Subjective effects include dissociative anaesthesia, perceptual distortion, cognitive disconnection, and dose-dependent ego dissolution. The experience is described as warmer and more immersive than ketamine, unfolding gradually and sustaining intensity over a broader temporal arc that invites contemplative introspection in calm settings. Disorientation, prolonged confusion, and impaired motor coordination are characteristic unsought effects.
Animal studies demonstrate both rewarding and reinforcing properties comparable to ketamine, indicating meaningful abuse liability;[5] no human lethal dose or organ toxicity threshold has been established. The longer duration increases cumulative NMDA blockade per session, potentially amplifying both psychological vulnerability and the organ-level risks documented for chronic ketamine use. No controlled human study of any kind has been published — the entire evidence base rests on animal pharmacology, in vitro data, forensic case reports, and community user reports.
History[edit]
Discovery
Deschloroketamine (DCK) bears CAS number 7063-30-1 and was first proposed as a candidate immunomodulatory and anti-infective agent during the 1960s — the same era of systematic arylcyclohexylamine exploration that produced ketamine and phencyclidine.[1] Despite its early synthesis, DCK never advanced into clinical development for any indication, and the specific patent or structure-activity paper that first described the compound has not been located in the published literature.citation needed
Emergence as a research chemical
DCK resurfaced on online research chemical platforms around 2015, triggering its first EMCDDA notification via the United Kingdom's Early Warning System in March of that year.[6] In some markets it was sold as "ketamine," misleading buyers who believed they were purchasing the parent compound.[6] The first published analytical characterisation of DCK from seized material appeared in 2016,[4] and systematic scientific investigation — including enantiomer synthesis, metabolite identification, and behavioural pharmacology — followed in a compressed timeline.
Modern research
Key milestones include the first enantiomer synthesis and cytotoxicity assessment in 2018,[1] metabolite identification in rat tissue in 2020,[6] the first post-mortem forensic case in 2021,[7] and the first systematic rat behavioural study and demonstration of self-administration in mice in 2022.[8][5] No clinical trials have been registered for deschloroketamine as of April 2026.
The name "deschloroketamine" is a systematic descriptor: des- (removal of) + chloro (the chlorine atom) + ketamine — literally, ketamine with its chlorine substituent stripped away. The abbreviation DCK predominates in research chemical communities and the analytical literature. The compound has no established street names distinct from its chemical designation, reflecting its niche circulation among informed research chemical users rather than broad recreational markets.
Chemistry[edit]
Structural class
Deschloroketamine belongs to the arylcyclohexylamine family — a chemical class defined by a cyclohexane ring bearing both a phenyl group and an amine. This scaffold is shared by ketamine, phencyclidine, and methoxetamine. DCK is structurally the simplest ketamine structural analog: it retains the 2-(methylamino)cyclohexanone core but lacks the chlorine atom on the phenyl ring that defines ketamine.
Removing the chlorine reduces both molecular weight and lipophilicity relative to ketamine. The unsubstituted phenyl ring also distinguishes DCK from 2-fluorodeschloroketamine, which carries a fluorine at the same position.
Molecular properties
| Molecular formula | C₁₃H₁₇NO |
| Molecular weight | 203.28 g/mol |
The IUPAC name is 2-(methylamino)-2-phenylcyclohexan-1-one. The molecule consists of a cyclohexanone ring with a ketone at C-1 and both a methylamino group and an unsubstituted phenyl ring at C-2.
Stereochemistry
DCK has one chirality centre at C-2, yielding two enantiomers: S-DCK and R-DCK. Absolute configuration was determined by vibrational and electronic circular dichroism and X-ray crystallography.[1] This mirrors the enantiomeric pharmacology of ketamine, where the S-form is consistently more potent.
S-DCK is approximately twice as cytotoxic as R-DCK in cell culture (IC₅₀ < 0.99 mM vs. ~1.82 mM in HEK 293T cells).[1] The racemic mixture is the form encountered on the unregulated market; enantiomerically pure DCK has not been reported in seized materials.
Physical properties
No peer-reviewed characterisation of DCK's melting point, solubility, or storage stability has been published. In pooled human liver microsomes, DCK shows the lowest protein binding of the ketamine analogues tested (unbound fraction 0.54–0.84), consistent with its lower lipophilicity relative to chlorinated relatives.[9]
Pharmacology[edit]
Mechanism of action
DCK functions as an uncompetitive NMDA receptor antagonist — it enters the ion channel only after the receptor has been activated by glutamate, then blocks ion flow in a use-dependent manner.[2][3] This is the same mechanism employed by ketamine, phencyclidine, and other arylcyclohexylamine dissociatives.[10]
No binding affinity data specific to DCK have been published at any receptor. The NMDA antagonist designation rests on structural analogy with ketamine and confirmatory behavioural pharmacology in rats.[8] A secondary classification as a sigma-1 receptor agonist appears in some databases but lacks any DCK-specific evidence.safety citation needed
Enantiomeric pharmacology
The S-enantiomer is consistently more active than R-DCK, paralleling the established potency relationship of ketamine's enantiomers. Rat studies confirm S-DCK as more active across behavioural and pharmacodynamic measures.[8] The racemic mixture is the only form reported in seized materials.
Behavioural pharmacology
In rats, DCK produces behavioural and addictive profiles similar to ketamine, with a slightly slower pharmacokinetic profile consistent with its longer duration.[8] In mice, DCK produces conditioned place preference (indicating reward) and self-administration (indicating reinforcement) — placing it closer to ketamine in dependence profile than compounds like diphenidine, which show reward without reinforcement.[5]
DCK also increases dopamine levels in cell culture,[5] consistent with the mesolimbic dopamine activation that underlies both the rewarding properties observed in animal models and the euphoric quality reported by users. Novel arylcyclohexylamines as a class produce phencyclidine-like abuse liability and psychosis-like neurocognitive effects in rodent models.[11]
Pharmacokinetics
No human pharmacokinetic studies exist. All data derive from rat studies and in vitro human liver microsome experiments.
DCK shows lower protein binding than other ketamine analogues tested (unbound fraction 0.54–0.84).[9] Hepatic clearance appears lower than that of ketamine or 2F-DCK, consistent with DCK's longer duration of action.[9]
In rats, DCK and its primary metabolite nordeschloroketamine (NDCK) achieve brain concentrations exceeding serum levels, confirming efficient central nervous system penetration.[6] The major metabolic route is N-demethylation to NDCK, with additional pathways including reduction, hydroxylation, and Phase II conjugation.[6][12]
DCK has been confirmed as a metabolite of 2-fluorodeschloroketamine in human liver microsomes.[13] Detection of DCK in biological samples does not always confirm primary DCK use — 2F-DCK ingestion must be ruled out.
Neuroscience[edit]
Where it acts
No direct neuroimaging or electrophysiology data exist for DCK. Based on the well-characterised neuroscience of ketamine, NMDA blockade disrupts thalamocortical signalling — the relay of sensory information from thalamus to cortex — producing the characteristic dissociative state. At lower doses this manifests as altered perception, depersonalisation, and cognitive disconnection; at higher doses, as near-complete dissociative anaesthesia.
DCK increases dopamine in cell culture,[5] consistent with mesolimbic activation that likely underlies both the rewarding properties seen in animal models and the euphoric quality reported by users.
Why it matters
The dominant explanatory framework is the cortical-subcortical disconnection model: NMDA blockade at thalamic relay nuclei impairs sensory gating to cortical areas, producing the perceptual distortions and bodily detachment that define the dissociative experience. A complementary model — the glutamate surge hypothesis — proposes that NMDA blockade on inhibitory interneurons paradoxically increases glutamate transmission, triggering neuroplastic cascades via AMPA activation and downstream BDNF release.
Whether DCK engages this synaptogenic pathway is unknown, but its longer duration of NMDA blockade could produce distinct temporal dynamics of synaptic potentiation relative to ketamine.
Key unknowns include whether DCK triggers rapid synaptogenesis through the same AMPA/BDNF pathway implicated in ketamine's antidepressant effects — and whether its longer receptor occupancy alters or amplifies that process. No data exist on whether chronic DCK use produces the white matter changes or bladder innervation damage observed with chronic ketamine.
Subjective Effects[edit]
DCK's experiential character is shaped by its gradual onset and sustained intensity relative to ketamine. Where ketamine compresses dissociation into a brief, steep arc, DCK unfolds more slowly, producing a spacious quality that users describe as warmer and more immersive. Set and setting exert substantial influence — the same dose can yield contemplative introspection in a calm environment or disorienting confusion in an unfamiliar one.
Within the dissociative class, DCK occupies a middle ground between ketamine's short, intense dissociation and the more protracted, sometimes manic character attributed to methoxetamine.[14] Route of administration markedly alters the experience: smoked DCK compresses the arc to under 90 minutes, while oral administration extends it across a much broader window with gentler transitions.
Effect Grid
At common doses, the full dissociative experience manifests: pronounced depersonalisation and derealisation, significant perceptual distortions including visual and auditory alterations, and a marked sense of disconnection from the body and environment. Cognitive effects include thought disorganisation, conceptual thinking, and a sense of profound novelty in familiar surroundings. Ego dissolution may begin at the upper end of this range.
Physically, substantial anaesthesia and motor incoordination are expected. Nystagmus, difficulty speaking, and impaired ambulation are common. Nausea is possible, particularly at onset. Duration commitment is significant: 4–6 hours oral, 3–6 hours insufflated.
Functional impairment is substantial. Operating machinery or navigating unfamiliar environments is unsafe.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perspective distortion · Depth perception distortion · Proprioceptive distortion · Vestibular distortion · Ganzfeld effect · Holotropic state · Visual drifting · Music enhancement · Auditory distortion · Visual haze / noise · Dreaming enhancement · Auditory suppression · Brightness alteration · Color alteration · Geometry · Peripheral vision distortion · Sleep-transition hallucinations · Tracers · Visual morphing · After-images · Auditory enhancement · Auditory misinterpretation · Color enhancement · Environmental patterning · Light sensitivity · Sound sensitivity · Symmetrical texture repetition · Visual breathing · Visual melting · Synesthesia · Color suppression · Peripheral misidentification · Tinnitus · Visual magnification · Visual processing suppression · Internal hallucinations · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations · External hallucinations · Object transformations · Object activation · Visual flipping · Visual recursion · Persisting hallucinations
Ganzfeld effect · Holotropic state · Visual drifting · Music enhancement · Auditory distortion · Visual haze / noise · Dreaming enhancement · Auditory suppression · Brightness alteration · Color alteration · Geometry · Peripheral vision distortion · Sleep-transition hallucinations · Tracers · Visual morphing · After-images · Auditory enhancement · Auditory misinterpretation · Color enhancement · Environmental patterning · Light sensitivity · Sound sensitivity · Symmetrical texture repetition · Visual breathing · Visual melting · Synesthesia · Color suppression · Peripheral misidentification · Tinnitus · Visual magnification · Visual processing suppression · Internal hallucinations · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations · External hallucinations · Object transformations · Object activation · Visual flipping · Visual recursion · Persisting hallucinations
Muscle relaxation · Bodily lightness · Dizziness · Body high · Body schema distortion · Physical fatigue · Tactile euphoria · Spontaneous body sensations · Laughter fits · Pupil dilation · Sexual arousal suppression · Nausea · Bodily heaviness · Bodily pressures · Headache · Nasal congestion · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Breathing alteration · Dry mouth · Heart rate perception changes · Insomnia · Stimulation · Involuntary body movements · Muscle tension · Trembling · Vomiting · Bodily dissociation · Phantom limb sensations · Tactile hallucination
Body schema distortion · Physical fatigue · Tactile euphoria · Spontaneous body sensations · Laughter fits · Pupil dilation · Sexual arousal suppression · Nausea · Bodily heaviness · Bodily pressures · Headache · Nasal congestion · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Breathing alteration · Dry mouth · Heart rate perception changes · Insomnia · Stimulation · Involuntary body movements · Muscle tension · Trembling · Vomiting · Bodily dissociation · Phantom limb sensations · Tactile hallucination
Information processing suppression · Memory fragmentation · Thought disorganization · Cognitive euphoria · Memory suppression · Analysis suppression · Thought deceleration · Immersion enhancement · Cognitive fatigue · Language suppression · Introspection enhancement · Pattern recognition suppression · Novelty enhancement · Openness enhancement · Suggestibility enhancement · Thought loops · Conceptual thinking · Aesthetic enhancement · Humor enhancement · Creativity enhancement · Creativity suppression · Delusions of sobriety · Motivation suppression · Multiple thought streams · Thought connectivity · Aesthetic suppression · Cognitive dysphoria · Cognitive flexibility · Memory replays · Analysis enhancement · Amnesia · Delirium · Delusions
Cognitive euphoria · Memory suppression · Analysis suppression · Thought deceleration · Immersion enhancement · Cognitive fatigue · Language suppression · Introspection enhancement · Pattern recognition suppression · Novelty enhancement · Openness enhancement · Thought loops · Conceptual thinking · Aesthetic enhancement · Humor enhancement · Creativity enhancement · Creativity suppression · Delusions of sobriety · Motivation suppression · Multiple thought streams · Thought connectivity · Aesthetic suppression · Cognitive dysphoria · Cognitive flexibility · Memory replays · Analysis enhancement · Amnesia · Delirium · Delusions
Anxiety · Dysphoria · Emotional enhancement · Emotional lability · Empathy suppression · Anhedonia · Catharsis · Empathy enhancement · Irritability · Simultaneous emotions · Mania
Emotional lability · Empathy suppression · Anhedonia · Catharsis · Empathy enhancement · Irritability · Simultaneous emotions
Social disconnection · Craving · Sociability suppression · Disinhibition · Automaticity · Emotional susceptibility · Flow state · Ego inflation · Social connection · Communication enhancement · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Automaticity · Emotional susceptibility · Flow state · Ego inflation · Social connection · Communication enhancement · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Time cessation
Death-rebirth sequence · Entity contact · Near-death experience · Non-dual awareness · Transpersonal feelings · Transpersonal visions
Transpersonal feelings · Transpersonal visions
Timeline
First alerts appear as a subtle sense of heaviness, mild cognitive slowing, and faint perceptual shifts. Easily mistaken for placebo at lower doses.
Dissociative effects build progressively: growing numbness, increasing cognitive disconnection, and emerging perceptual distortions. Nausea is most likely during this phase.
Maximum dissociation is reached. At common doses, pronounced depersonalisation, perceptual distortions, and motor incoordination dominate. At strong doses, immersive internal experiences and ego dissolution occur.
Intensity diminishes gradually but dissociative effects persist. Cognitive function begins to return, though perception remains altered and coordination impaired.
Progressive reconnection with baseline perception. Residual numbness, mild cognitive fog, and gentle mood changes linger. Motor coordination improves but remains subtly impaired.
Residual effects include mild mood elevation or flattening, subtle cognitive changes, and possible disrupted sleep architecture. Some users report a contemplative or reflective quality lasting hours to a day.
⚠ Do not drive or operate heavy machinery for at least 12 hours after the subjective experience ends, as residual dissociative impairment may persist beyond conscious awareness.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · phencyclidine · methoxetamine
Toxicity
Acute toxicity
No human lethal dose or safe dose ceiling has been established for DCK.[1] Lab studies show low acute cell toxicity, but these values don't translate to safe human doses.[1] At high concentrations, zebrafish larvae show complete mortality.[12]
Cardiovascular effects
DCK raises blood pressure and heart rate — a cardiovascular stimulant pattern documented in clinical presentations.[13] This is expected across the arylcyclohexylamine class, and similar brain temperature increases documented with ketamine are anticipated for DCK.[14]
Organ toxicity
No DCK-specific organ damage has been documented. Chronic ketamine use causes bladder fibrosis and liver complications; these risks are plausible for DCK by structural similarity.safety citation needed DCK's longer duration means more organ exposure per session than an equivalent ketamine session.
Fatal cases
No published death identifies DCK as the sole cause. All reported deaths involve multiple substances — a traumatic fall with DCK detected post-mortem,[7] and fatal polydrug intoxications where other compounds were dominant.[15][16]
Psychological risks
Paranoia, confusion, agitation, and psychosis-like thinking can occur at sub-anaesthetic doses — a pattern documented across the arylcyclohexylamine class.[17][18] Clinical presentations involving DCK have included impaired consciousness, agitation, and convulsions.[13]
DCK's longer duration extends the window of psychological vulnerability. Chronic use of glutamate-blocking compounds is associated with lasting memory and executive function impairment, and DCK's prolonged blockade per session may compound this over time.
Tolerance and dependence
Tolerance builds with repeated use as the brain compensates through changes in glutamate signaling. Cross-tolerance is expected with Ketamine, PCP, MXE, and 2F-DCK. Community estimates place the half-life at approximately 5 days and full reset at roughly 1.5 weeks[11] — unconfirmed by controlled research.
Animal studies confirm meaningful abuse liability: DCK produces both rewarding and reinforcement in mice, alongside raised dopamine levels.[5] This places it in the same reinforcement category as ketamine.[8] User reports corroborate this — 5 of 35 Erowid experience reports fall under "addiction and habituation".[19]
Drug Interactions
No DCK-specific interaction studies exist. All data come from ketamine class pharmacology and polydrug forensic cases.
NMDA antagonist combinations
Combining DCK with other dissociatives produces additive anaesthetic effects. In a 20-patient case series, 19 of 20 presentations included at least one other ketamine-type drug.[13] This polydrug pattern risks unexpectedly deep anaesthetic states.
Opioid combinations
Glutamate-blocking drugs worsen the brain oxygen depletion caused by opioids. Ketamine combined with fentanyl produces greater oxygen loss than either drug alone, while also masking visible signs of breathing failure.[14] This interaction is expected to apply to DCK and is life-threatening.
CNS depressant combinations
Alcohol, benzodiazepines, and other sedatives add to DCK's sedating effects and increase the risk of respiratory depression.[3] At least one polydrug fatality involving arylcyclohexylamine compounds included concurrent depressant use.[16]
Stimulant combinations
Stimulants have been detected alongside dissociatives in fatal cases.[16] Combining them with DCK may amplify cardiovascular strain — elevated blood pressure, rapid heart rate, and irregular rhythm — because both exert stimulant effects on the heart and blood vessels.
Serotonergic combinations
MAOI and tramadol combinations carry a theoretical risk of serotonin overload — a dangerous condition involving overheating, racing heart, and seizures. No DCK-specific data exist.safety citation needed
Contraindications
7 knownNo DCK-specific contraindication data have been published. The following are inferred from arylcyclohexylamine class pharmacology.
Absolute: Personal or family history of psychotic disorders — glutamate-blocking drugs can trigger or worsen psychosis.[17] Pregnancy — glutamate receptor signaling is critical to fetal brain development, and no reproductive safety data exist.
Relative: Heart conditions (elevated blood pressure and heart rate documented in clinical cases);[13] seizure disorders (convulsions observed in clinical presentations);[13] liver impairment; bladder conditions; concurrent use of CNS depressants, opioids, or MAOIs.
Harm Reduction[edit]
Forms & Identification
DCK circulates as a white to off-white crystalline powder. Because it has been sold as "ketamine" in some markets,[4] reagent testing alone cannot reliably distinguish it from ketamine or other arylcyclohexylamine analogues. Quantitative drug checking services provide the most reliable identification where available.
DCK's higher weight-potency relative to ketamine means a user accustomed to ketamine dosing may inadvertently take a far stronger dose if they receive DCK instead. Potency also varies between batches.
Guidelines
- Test every batch with a reagent kit and, where possible, a quantitative drug checking service
- Start with a low dose and wait for full onset before considering redosing — oral onset can be slow and the long duration means doses compound
- Avoid redosing during the experience; the extended duration makes it easy to overshoot
- Have a sober sitter present, especially at higher doses
- Stay hydrated but do not force fluid intake
- Keep the environment warm, quiet, and physically safe — remove tripping hazards and sharp objects
- Do not operate vehicles or machinery for the full duration and several hours after
Set & Setting
DCK's extended duration demands more advance planning than shorter dissociatives. A safe physical environment free of fall hazards is essential — motor impairment and spatial disorientation persist for hours. A calm, familiar setting reduces the likelihood of confusion becoming distressing.
A sober, trusted companion is strongly recommended, particularly at moderate-to-high doses where the person may be unable to communicate or move safely for extended periods.
Aftercare & integration. The hours after a DCK experience often bring lingering cognitive fog, reduced coordination, and emotional flatness. Allow a full day for recovery before returning to demanding tasks. Sleep may be disrupted the night of use.
Re-grounding techniques — physical movement, warm food, familiar music, contact with trusted people — help restore connection to the body. If the experience surfaced difficult emotions or memories, writing about them within 24–48 hours can support processing. Persistent feelings of unreality or numbness lasting more than a few days warrant consultation with a mental health professional.
Recovery & Support
DCK's reinforcing properties and long duration can establish patterns of habitual use. Warning signs include escalating doses to achieve the same effect, difficulty taking extended breaks, and using DCK to manage emotions or avoid discomfort.
Professional support is available if use has become compulsive. Addiction counsellors, harm reduction organisations, and peer support communities can help. Online resources such as SMART Recovery and local substance use services offer confidential assistance. Gradual reduction is generally well-tolerated for dissociatives, but professional guidance is recommended for heavy or long-term use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: Unresponsiveness beyond expected dissociation, seizures, chest pain, vomiting while unconscious, blue or grey lips, extremely slow or stopped breathing, and severe agitation with self-harm risk all require immediate help.
Immediate steps:
- 1. Call emergency services
- 2. Place an unconscious person in the recovery position (on their side) to prevent choking
- 3. Do not leave them alone
- 4. Do not restrain unless they are in immediate physical danger
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (deschloroketamine/DCK), approximate amount taken, time of ingestion, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for arylcyclohexylamine overdose.
Legal Status[edit]
Overview
DCK is not specifically scheduled in most jurisdictions but is controlled in the United Kingdom and several other countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not listed in the Controlled Substances Act schedules. May be subject to the Federal Analogue Act (21 U.S.C. § 813) as a structural analogue of ketamine (Schedule III), though the Act's strict text references Schedules I and II only. DEA seized DCK on at least 8 occasions in 2016. No published case law confirming analogue act prosecution for DCK[9] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under the arylcyclohexylamine generic clause (Statutory Instrument 2013/239, effective 26 February 2013) — predating DCK's emergence by two years. Possession, supply, production, and import are illegal |
| Switzerland | Controlled (Verzeichnis E) | Scheduled under narcotics legislation |
| Austria | Controlled (NPSV) | Listed under the Neue-Psychoaktive-Substanzen-Verordnung |
| Czech Republic | Not specifically controlled | Legal as of April 2026 |
| Netherlands | Not specifically controlled | Legal as of early 2025, pending scheduled review |
| Latvia | Controlled | Specifically scheduled |
Legal status data for individual European jurisdictions are sourced from regulatory monitoring databases and may not reflect recent amendments.citation needed Australian and Canadian scheduling status for DCK has not been confirmed against primary regulatory documents.citation needed
Legal status changes frequently and varies by jurisdiction. This is not legal advice — verify current status with local legal resources before drawing conclusions about specific activities.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · phencyclidine · methoxetamine
Toxicity
Acute toxicity
No human lethal dose, therapeutic index, or safe-dose ceiling has been established for DCK. In vitro cell studies show millimolar-range toxicity thresholds — suggesting relatively low acute cytotoxicity at the cellular level — but these values do not translate directly to safe human doses.[1] Zebrafish studies show complete larval mortality at high concentrations, though early embryos are unaffected due to the absence of NMDA receptors at that developmental stage.[15]
Cardiovascular effects
Blood pressure increases and elevated heart rate are reported in clinical presentations involving DCK.[16] These sympathomimetic effects — vasoconstriction and increased cardiac output — are expected from the arylcyclohexylamine class. Ketamine is known to increase brain temperature and metabolic activity at sub-anaesthetic doses, and similar effects are anticipated for DCK.[17]
Organ toxicity
No DCK-specific organ damage has been documented. Chronic ketamine use causes well-established bladder damage (fibrosis, contracted bladder, upper urinary tract injury) and liver complications. These risks are plausible for DCK given structural similarity, and the longer duration of action raises the possibility of prolonged organ exposure per session.safety citation needed
Fatal cases
No published fatality identifies DCK alone as the cause of death. All reported deaths involve multiple substances: traumatic death after a fall with DCK and other dissociatives detected post-mortem,[7] and fatal polydrug intoxications where other compounds were present at higher concentrations.[18][19]
Psychological risks
No controlled studies have assessed DCK-specific psychological risks. The arylcyclohexylamine class broadly produces paranoia, confusion, agitation, and psychosis-like cognitive impairment at sub-anaesthetic doses.[11][20] Clinical case reports document impaired consciousness, agitation, and abnormal behaviour in presentations involving DCK, with convulsions occurring in a subset of cases.[16]
DCK's longer duration relative to ketamine prolongs the window of psychological vulnerability and disorientation. Chronic NMDA antagonist use is associated with persistent memory and executive function deficits, and DCK's extended blockade per session may amplify cumulative exposure.
Tolerance and dependence
Tolerance develops with repeated use through compensatory changes in NMDA receptor density and glutamate signalling. Cross-tolerance is expected with all dissociatives sharing the NMDA antagonist mechanism, including Ketamine, PCP, MXE, and 2F-DCK.
Community estimates place the tolerance half-life at approximately 5 days, with full reset at roughly 1.5 weeks.[14] These values lack controlled confirmation.
Animal data support meaningful abuse liability: DCK produces both conditioned place preference (rewarding) and self-administration (reinforcing) in mice, with concurrent dopamine activation.[5] This dual profile places DCK in the same reinforcement category as ketamine.[8] User reports corroborate dependence potential — 5 of 35 Erowid experience reports fall under "addiction and habituation".[21]
Drug Interactions
No DCK-specific drug interaction studies have been published. All interaction data derive from ketamine class pharmacology and polydrug forensic cases.
NMDA antagonist combinations
Combining DCK with other dissociatives produces additive or synergistic anaesthetic effects. In a 20-patient case series, at least one additional ketamine-type drug was detected in 19 of 20 cases, with DCK present in half.[16] This polydrug pattern risks unexpectedly deep anaesthetic states.
Opioid combinations
NMDA antagonists worsen opioid-induced brain oxygen depletion. Ketamine combined with fentanyl produces greater brain oxygen loss than either drug alone, while also constricting blood vessels in ways that can mask visible signs of respiratory failure.[17] This interaction is expected to apply to DCK and represents a life-threatening risk.
CNS depressant combinations
Additive sedation and respiratory depression are anticipated when DCK is combined with alcohol, benzodiazepines, or other sedatives.[3] At least one polydrug fatality involving arylcyclohexylamine compounds occurred with concurrent depressant use.[19]
Stimulant combinations
Stimulants have been detected alongside dissociatives in fatal cases.[19] Cardiovascular strain — elevated blood pressure, rapid heart rate, irregular rhythm — may be amplified when NMDA antagonist sympathomimetic effects combine with direct stimulant action.
Serotonergic combinations
MAOI and tramadol combinations carry theoretical serotonin syndrome risk based on the serotonergic activity of some arylcyclohexylamines. No DCK-specific data exist.safety citation needed
Contraindications
7 knownNo DCK-specific contraindication data have been published. The following are inferred from arylcyclohexylamine class pharmacology:
Absolute: Personal or family history of psychotic disorders — NMDA antagonists can precipitate or worsen psychosis.[11] Pregnancy — NMDA receptor signalling is critical to foetal brain development, and no reproductive safety data exist.
Relative: Heart conditions (elevated blood pressure and heart rate documented in clinical cases);[16] seizure disorders (convulsions observed in clinical presentations);[16] liver impairment; bladder conditions (ketamine bladder damage risk by class analogy); concurrent use of CNS depressants, opioids, or MAOIs.
Harm Reduction[edit]
Forms & Identification
DCK circulates primarily as a white to off-white crystalline powder. Because it has been sold as "ketamine" in some markets,[6] substance identity verification is especially important — reagent testing alone cannot reliably distinguish DCK from ketamine or other arylcyclohexylamine analogues. Quantitative analysis through drug checking services, where available, provides the most reliable identification.
Potency varies between batches, and DCK's higher weight-potency relative to ketamine means users accustomed to ketamine dosing may inadvertently take a much stronger dose if they receive DCK instead.
Guidelines
- Test every batch with a reagent kit and, where possible, a quantitative drug checking service
- Start with a low dose and wait for full onset before considering redosing — oral onset can be slow and the long duration means doses compound
- Avoid redosing during the experience; the extended duration makes it easy to overshoot
- Have a sober sitter present, especially at higher doses
- Stay hydrated but do not force fluid intake
- Keep the environment warm, quiet, and physically safe — remove tripping hazards and sharp objects
- Do not operate vehicles or machinery for the full duration and several hours after
Set & Setting
DCK's extended duration demands more advance planning than shorter dissociatives. Ensure a safe physical environment free of fall hazards — motor impairment and spatial disorientation persist for hours. A calm, familiar setting reduces the likelihood of confusion becoming distressing.
A sober, trusted companion is strongly recommended, particularly at moderate-to-high doses where the user may be unable to communicate or move safely for extended periods.
Aftercare & integration. The hours following a DCK experience often involve lingering cognitive fog, reduced coordination, and emotional flatness. Allow a full day for recovery before returning to demanding tasks. Sleep may be disrupted the night of use.
Re-grounding techniques — physical movement, warm food, familiar music, contact with trusted people — help restore connection to the body and environment. If the experience surfaced difficult emotions or memories, writing about them within the first 24–48 hours can support processing. Persistent feelings of unreality, anxiety, or emotional numbness lasting more than a few days warrant consultation with a mental health professional.
Recovery & Support
DCK's reinforcing properties and long duration can establish patterns of habitual use. Warning signs include escalating doses to achieve the same effect, difficulty taking extended breaks, and using DCK to manage emotions or avoid discomfort.
Professional support is available if use has become compulsive. Addiction counsellors, harm reduction organisations, and peer support communities can help. Online resources such as SMART Recovery and local substance use services offer confidential assistance. Reducing frequency gradually is generally well-tolerated for dissociatives, but professional guidance is recommended for heavy or long-term use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: Unresponsiveness beyond expected dissociation, seizures, chest pain, vomiting while unconscious, blue or grey lips, extremely slow or stopped breathing, and severe agitation with self-harm risk all require immediate help.
Immediate steps:
- 1. Call emergency services
- 2. Place an unconscious person in the recovery position (on their side) to prevent choking
- 3. Do not leave them alone
- 4. Do not restrain unless they are in immediate physical danger
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (deschloroketamine/DCK), approximate amount taken, time of ingestion, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for arylcyclohexylamine overdose.
Legal Status[edit]
Overview
Deschloroketamine occupies an ambiguous legal position internationally. It is not specifically scheduled in many jurisdictions but is controlled in the United Kingdom under a generic arylcyclohexylamine clause that predates its appearance on the recreational market. In the United States it remains unscheduled at the federal level but may fall under structural analog legislation when intended for human consumption. No jurisdiction has established a regulated medical framework for DCK.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | Not listed in the Controlled Substances Act schedules. May be subject to the Federal Analogue Act (21 U.S.C. § 813) as a structural analogue of ketamine (Schedule III), though the Act's strict text references Schedules I and II only. DEA seized DCK on at least 8 occasions in 2016. No published case law confirming analogue act prosecution for DCK[10] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under the arylcyclohexylamine generic clause (Statutory Instrument 2013/239, effective 26 February 2013) — predating DCK's emergence by two years. Possession, supply, production, and import are illegal |
| Switzerland | Controlled (Verzeichnis E) | Scheduled under narcotics legislation |
| Austria | Controlled (NPSV) | Listed under the Neue-Psychoaktive-Substanzen-Verordnung |
| Czech Republic | Not specifically controlled | Legal as of April 2026 |
| Netherlands | Not specifically controlled | Legal as of early 2025, pending scheduled review |
| Latvia | Controlled | Specifically scheduled |
Legal status data for individual European jurisdictions are sourced from regulatory monitoring databases and may not reflect recent amendments.citation needed Australian and Canadian scheduling status for DCK has not been confirmed against primary regulatory documents.citation needed
Analogue act considerations
The US Federal Analogue Act (21 U.S.C. § 813) permits prosecution of "substantially similar" chemical analogues of Schedule I or II controlled substances when intended for human consumption. Ketamine is classified under Schedule III, which technically places it outside the strict statutory scope of the Analogue Act. State-level analogue laws vary and may apply more broadly. The legal applicability of federal or state analogue provisions to DCK has not been tested in published case law.citation needed
Frequently asked questions
What is Deschloroketamine?
Deschloroketamine (DCK) is a dissociative anaesthetic of the arylcyclohexylamine class, the dechlorinated structural analogue of ketamine. It acts as an NMDA receptor antagonist with a longer oral duration (4–6 hours) and has been sold on research-chemical markets since circa 2015.
How long does Deschloroketamine last?
Total duration by route of administration — Oral: 4 – 6 hours; Insufflated: 3 – 6 hours; Smoked: 30 – 90 min. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Deschloroketamine?
Psychedex publishes a dosage table for Deschloroketamine on this page covering these routes of administration: insufflated, oral, smoked. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Deschloroketamine?
The highest-severity documented interactions for Deschloroketamine: GHB, GBL (Lethal), Anticholinergics (Dangerous), Antihistamines (Dangerous), Antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Deschloroketamine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Deschloroketamine: tolerance builds moderate; full reset takes 10 days; cross-tolerance develops with ketamine, phencyclidine, methoxetamine, 2-fluorodeschloroketamine, 3-MeO-PCP, dextromethorphan. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [3] ^abcLuethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [4] ^abcdefHájková K, Jurásek B, Čejka J, Štefková K, Páleníček T, Sýkora D, Kuchař M (2020) Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry — Drug Testing and Analysis doi:10.1002/dta.2726
- [5]
- [6] ^Frison G, Zamengo L, Zancanaro F, Tisato F, Traldi P (2016) Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance — Rapid Communications in Mass Spectrometry doi:10.1002/rcm.7425
references
- [1]
- [2] ^abWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [3] ^abcLuethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [4] ^abFrison G, Zamengo L, Zancanaro F, Tisato F, Traldi P (2016) Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance — Rapid Communications in Mass Spectrometry doi:10.1002/rcm.7425
- [5]
- [6] ^abcdefHájková K, Jurásek B, Čejka J, Štefková K, Páleníček T, Sýkora D, Kuchař M (2020) Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry — Drug Testing and Analysis doi:10.1002/dta.2726